

AMENDMENT

Claim Listing

1. (presently amended) A compound comprising a steroid hormone selected from the group consisting of glucocorticoids, mineralcorticoids, androgens and estrogens, said steroid hormone being stably linked via a spacer of 5-15 atoms to a DNA-incorporating DNA-interacting molecule, wherein the steroid hormone is linked via a first urethane bond to the spacer and the spacer is linked via a second urethane bond to the DNA-incorporating molecule.

2-5. (canceled)

6. (original) The compound of claim 1, wherein the spacer contains 5-15 atoms.

7. (original) The compound of claim 1, wherein the spacer contains 9-11 atoms.

8. (canceled)

9. (original) The compound of claim 4, wherein the steroid hormone is linked via a first urethane bond to the spacer and the spacer is linked via a second urethane bond to the DNA-interacting molecule.

10. (presently amended) The compound of claim 1, wherein the urethane bond is positioned either at carbon atom[s] 1, 2, 4, 6, 7, 11 α [11a], 12, 15, 16, 17 or 21 of the [a] glucocorticoid.

11. (presently amended) The compound of claim 1, [10], wherein the urethane bond is positioned either at carbon atom 6 or 21 of the [a] glucocorticoid.

12-13. (canceled)

14. (presently amended) The compound of claim 1 [13], wherein the DNA-incorporating [DNA-interacting] molecule is a psoralen [selected from the group consisting of intercalating agents, crosslinking reagents, incorporating molecules and ionically interacting molecules].

15-16. (canceled)

17. (presently amended) A method for the preparation of the compound according to claim 1 comprising the steps of ligating a spacer of 5-15 atoms to the steroid

*B1
Omit*

hormone via an urethane bond and ligating the DNA-incorporating [to a DNA-interacting] molecule via an urethane bond to the spacer.

18-19. (canceled)

20. (withdrawn) A complex consisting of a compound of claim 1 commplexed to a nucleic acid molecule.

21. (withdrawn) A method for the preparation of the complex of claim 20 comprising the steps of ligating a steroid hormone to a DNA-interacting molecule to form a compound and complexing the compound with a nucleic acid molecule.

22. (withdrawn) The method of claim 21 further comprising the steps of ligating a spacer to the steroid hormone and ligating the DNA-interacting molecule to the spacer.

23. (withdrawn) Use of the complex of claim 20 for introducing a nucleic acid molecule into the nucleus of a cell.

24. (withdrawn) Use of the complex of claim 20 for introducing a DNA molecule into the nucleus of a non-dividing cell.

25. (withdrawn) A cell transfected with a complex according to claim 20.

26. (withdrawn) Use of a cell according to claim 25 for the medical treatment of a human being.

27. (withdrawn) A pharmaceutical preparation comprising the complex of claim 20 and a physiologically tolerable carrier.

28. (withdrawn) A method for transfecting cells comprising the step of administering a therapeutically effective amount of a complex according to claim 20 to a subject.

29. (withdrawn) An assay comprising the steps of

- transfecting cells with a complex of claim 20, wherein the DNA molecule contains an expressible gene;
- monitoring the expression of said expressible gene, and
- comparing the expression of said expressible gene in transfected cells with the expression of said expressible gene in non-transfected cells.

30. (original) The compound of claim 1, wherein the spacer contains 10 atoms.

31. (presently amended) The compound of claim 1 [15], wherein the spacer contains 9 to 11 atoms.

(B)
C-10
32. (new) The compound of claim 1, wherein the steroid hormone is a glucocorticoid hormone.

33. (new) The compound of claim 2, wherein the glucocorticoid hormone is selected from dexamethasone and cortisol.